NanoViricides, Inc. (NYSE MKT: NNVC) a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, announced today that it has entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale of 6,944,446 units at a price of $0.36 per unit. Each unit comprises 1 share of common stock and 1 five-year warrant exercisable at $0.61.

Chardan acted as the placement agent in connection with the financing. The closing of the sale of the securities is expected to take place on or about February 27, 2019, subject to the satisfaction of customary closing conditions.

About NanoViricides 

NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.